Dataset from A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00007752
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy
results in a clinically significant improvement in progression free survival (PFS) as
compared to treatment with ofatumumab in patients with relapsed or refractory Chronic
Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
创建时间：
2024-11-26
